摘要
目的探究钙离子拮抗剂联合替格瑞洛治疗高血压合并不稳定性心绞痛(UAP)的效果及其对炎症-微循环状态、主要心血管不良事件(MACE)发生率的影响。方法选取2021年1月至2022年12月该院收治的120例高血压合并UAP患者作为研究对象,按照抽签法分为常规组(60例)和试验组(60例)。常规组采用替格瑞洛治疗,试验组采用硝苯地平缓释片联合替格瑞洛治疗。比较两组临床疗效、治疗前后舒张压、收缩压、血脂[血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)]水平、心肌微循环指标(振幅、灌注达峰时间、造影剂开始灌注时间)水平、脑钠肽(BNP)水平、血清炎症因子[超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子(TNF-α)]水平、MACE发生率及不良反应发生率。结果治疗后试验组临床总有效率(95.00%)高于常规组(83.33%),差异有统计学意义(χ^(2)=4.227,P=0.040)。治疗后两组舒张压、收缩压、TG、TC及LDL-C水平均降低,且试验组均低于常规组,差异有统计学意义(P<0.05)。治疗后两组IL-6、hs-CRP、BNP及TNF-α水平均降低,且试验组均低于常规组,差异有统计学意义(P<0.05)。治疗后试验组MACE发生率(3.33%)低于常规组(13.33%),差异有统计学意义(χ^(2)=3.927,P=0.048)。结论钙离子拮抗剂联合替格瑞洛治疗高血压合并UAP疗效显著,可降低患者血压血脂水平,抑制炎症反应发展,改善心肌微循环,降低MACE发生率。
Objective To explore the effect of calcium channel blocker combined with ticagrelor in the treatment of hypertension complicated with unstable angina pectoris(UAP)and its influence on inflammation-microcirculation status and the incidence of major adverse cardiovascular events(MACE).Methods A total of 120 patients with hypertension and UAP admitted to the hospital from January 2021 to December 2022 were selected as the research objects.According to the lottery method,they were divided into conventional group(60 cases)and experimental group(60 cases).The conventional group was treated with ticagrelor,and experimental group was treated with nifedipine sustained-release tablets combined with ticagrelor.The clinical efficacy,diastolic blood pressure,systolic blood pressure,blood lipid[serum total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),triglyceride(TG)]level,myocardial microcirculation index(amplitude,perfusion peak time,contrast agent start perfusion time)level,brain natriuretic peptide(BNP)level,serum inflammatory factors before and after treatment were compared between the 2 groups The levels of high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),tumor necrosis factorα(TNF-α),the incidence of MACE and the incidence of adverse reactions.Results After treatment,the total effective rate of experimental group(95.00%)was higher than that of conventional group(83.33%),and the difference was statistically significant(χ^(2)=4.227,P=0.040).After treatment,the diastolic blood pressure,systolic blood pressure,TG,TC and LDL-C levels of the 2 groups were decreased,and experimental group was lower than conventional group,and the differences were statistically significant(P<0.05).After treatment,the levels of IL-6,hs-CRP,BNP and TNF-α in the 2 groups were decreased,and experimental group was lower than conventional group,and the differences were statistically significant(P<0.05).After treatment,the incidence of MACE in experimental group(3.33%)was lower than that in conventional group(13.33%),a
作者
宋涛
SONG Tao(Department of Cardiology,Shangqiu Hospital of Traditional Chinese Medicine in Henan Province,Shangqiu,Henan 476000,China)
出处
《检验医学与临床》
CAS
2023年第23期3485-3488,3492,共5页
Laboratory Medicine and Clinic
关键词
钙离子拮抗剂
替格瑞洛
高血压
不稳定性心绞痛
calcium channel blocker
ticagrelor
high blood pressure
unstable angina pectoris
